Avapritinib resistance of kit mutants
AssigneeBlueprint Medicines Corporation
InventorOleg Schmidt-Kittler
Life of this patent
Estimating the term…
Abstract
The disclosure includes methods of treating a patient suffering from a malignant disease driven by activating mutations in KIT, said method comprising: (a) obtaining a biological sample from the patient; (b) detecting the presence or absence of a KIT mutation selected from V654A in exon 13, N655T in exon 13, and T670I in exon 14 in the biological sample; and (c) administering a KIT inhibitor to the patient if the mutation is not detected.
Claims27
A method for treating a patient suffering from a malignant disease driven by activating mutations in KIT, said method comprising:
- (a) obtaining a biological sample from the patient;
- (b) detecting the presence or absence of a KIT mutation selected from V654A in exon 13, N655T in exon 13, and T670I in exon 14 in the biological sample;
- and
- (c) administering a KIT inhibitor to the patient if the mutation is not detected.
5-15. (canceled)
19-23. (canceled)
25-30. (canceled)
A method of predicting whether a patient suffering from a malignant disease will be responsive to treatment with a KIT inhibitor, comprising:
- (a) obtaining a biological sample from a patient;
- (b) detecting the presence or absence of a KIT mutation selected from V654A in exon 13, N655T in exon 13, and T670I in exon 14 in the biological sample;
- and
- (c) if the KIT mutation is absent from the biological sample, concluding that the patient will be responsive to a KIT inhibitor, and if the KIT mutation is present, concluding the patient will be nonresponsive to treatment with a KIT inhibitor.
35-43. (canceled)
47-53. (canceled)
A method of predicting whether a tumor will be responsive to treatment with a KIT inhibitor, comprising:
- (a) obtaining a biological sample from a patient suffering from a cancer;
- (b) detecting the presence or absence of a KIT mutation selected from V654A in exon 13, N655T in exon 13, and T670I in exon 14 in the biological sample;
- and
- (c) if the KIT mutation is absent from the biological sample, concluding that the tumor will be responsive to treatment with a KIT inhibitor, and if the KIT mutation is present, concluding the tumor will be nonresponsive to treatment with a KIT inhibitor.
58-65. (canceled)
The method of claim 65, wherein the cancer is gastrointestinal stromal tumor (GIST).
67-97. (canceled)
Dependencies are inferred from the claim text.